Loading
Re-analysing the PORTEC-3 trial by molecular class showed that p53-abnormal endometrial cancers gained substantially from adding chemotherapy to radiotherapy, POLE-mutated tumours did well regardless, and the other groups gained little.
Molecular classification of 410 high-risk endometrial cancers from the PORTEC-3 trial (chemoradiotherapy versus radiotherapy) into p53-abnormal, POLE-mutated, mismatch repair-deficient and no specific molecular profile groups.
Five-year recurrence-free survival for p53-abnormal tumours was 59 percent with chemoradiotherapy against 36 percent with radiotherapy alone; POLE-mutated tumours had 96 to 100 percent recurrence-free survival in both arms; mismatch repair-deficient and no specific molecular profile groups showed no significant benefit from chemotherapy.
Molecular class is now a predictive factor for adjuvant therapy: chemotherapy for p53-abnormal disease, de-escalation for POLE-mutated tumours, and trials of immunotherapy for mismatch repair-deficient disease.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Mismatch-repair-deficient endometrial cancer.
Shares PORTEC-3, p53-abnormal endometrial cancer, including uterine serous carcinoma.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
Shares PORTEC-3, POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Mismatch-repair-deficient endometrial cancer.
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Mismatch-repair-deficient endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Journal of Clinical Oncology.
Shares POLE-ultramutated endometrial cancer, Mismatch-repair-deficient endometrial cancer.
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Journal of Clinical Oncology.